Tirzepatide

metabolic-function

Verified

A dual GIP and GLP-1 receptor agonist FDA-approved for type 2 diabetes and obesity. It uniquely activates both incretin receptors, providing superior glycemic control and weight loss compared to GLP-1 agonists alone.

Chemical Information

Source:

Synthetic 39-amino acid peptide with GIP and GLP-1 receptor dual agonism. Modified with C20 fatty diacid for extended half-life. Brand names: Mounjaro, Zepbound.

Clinical Information

Purposes:

Type 2 diabetes management

Weight loss

Metabolic syndrome improvement

Appetite control

Dosing:

Start at 2.5mg weekly for 4 weeks, then escalate by 2.5mg every 4 weeks to maintenance dose of 5-15mg weekly.

Related Peptides:

Semaglutide

Liraglutide

GIP

Safety Information

Side Effects:

Nausea
Diarrhea
Decreased appetite
Vomiting
Constipation
Abdominal pain
Injection site reactions

Contraindications:

Personal or family history of medullary thyroid carcinoma
Multiple endocrine neoplasia syndrome type 2
Pregnancy or breastfeeding
Severe gastrointestinal disease

Research & References

Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515.
https://pubmed.ncbi.nlm.nih.gov/35658024/

Last updated: 12/20/2025 at 12:19:13 AM

Version: 1

Detailed Information

Primary Uses